Click for best price
Biosimilars Insulin Market Size, Share 2023
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called ?Insulin glargine? and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first ?biosimilar? insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
This report aims to provide a comprehensive presentation of the global market for Biosimilars Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Insulin. This report contains market size and forecasts of Biosimilars Insulin in global, including the following market information:
Global Biosimilars Insulin Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Biosimilars Insulin Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Biosimilars Insulin companies in 2022 (%)
The global Biosimilars Insulin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi?s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
We surveyed the Biosimilars Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilars Insulin Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, by Type, 2022 (%)
Insulin Glargine
Insulin Aspart
Insulin Lispro
Other
Global Biosimilars Insulin Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, by Application, 2022 (%)
Type I Diabetes
Type II Diabetes
Global Biosimilars Insulin Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilars Insulin revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Biosimilars Insulin revenues share in global market, 2022 (%)
Key companies Biosimilars Insulin sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Biosimilars Insulin sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Boehringer Ingelheim
Biocon/Mylan
Gan & Lee Pharmaceuticals
Tonghua Dongbao
United Laboratories
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biosimilars Insulin, market overview.
Chapter 2: Global Biosimilars Insulin market size in revenue and volume.
Chapter 3: Detailed analysis of Biosimilars Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilars Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Biosimilars Insulin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Biosimilars Insulin Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
79 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Biosimilars Insulin Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biosimilars Insulin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biosimilars Insulin Overall Market Size
2.1 Global Biosimilars Insulin Market Size: 2022 VS 2029
2.2 Global Biosimilars Insulin Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Biosimilars Insulin Sales: 2018-2029
3 Company Landscape
3.1 Top Biosimilars Insulin Players in Global Market
3.2 Top Global Biosimilars Insulin Companies Ranked by Revenue
3.3 Global Biosimilars Insulin Revenue by Companies
3.4 Global Biosimilars Insulin Sales by Companies
3.5 Global Biosimilars Insulin Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Biosimilars Insulin Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Biosimilars Insulin Product Type
3.8 Tier 1, Tier 2 and Tier 3 Biosimilars Insulin Players in Global Market
3.8.1 List of Global Tier 1 Biosimilars Insulin Companies
3.8.2 List of Global Tier 2 and Tier 3 Biosimilars Insulin Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Biosimilars Insulin Market Size Markets, 2022 & 2029
4.1.2 Insulin Glargine
4.1.3 Insulin Aspart
4.1.4 Insulin Lispro
4.1.5 Other
4.2 By Type - Global Biosimilars Insulin Revenue & Forecasts
4.2.1 By Type - Global Biosimilars Insulin Revenue, 2018-2023
4.2.2 By Type - Global Biosimilars Insulin Revenue, 2024-2029
4.2.3 By Type - Global Biosimilars Insulin Revenue Market Share, 2018-2029
4.3 By Type - Global Biosimilars Insulin Sales & Forecasts
4.3.1 By Type - Global Biosimilars Insulin Sales, 2018-2023
4.3.2 By Type - Global Biosimilars Insulin Sales, 2024-2029
4.3.3 By Type - Global Biosimilars Insulin Sales Market Share, 2018-2029
4.4 By Type - Global Biosimilars Insulin Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Biosimilars Insulin Market Size, 2022 & 2029
5.1.2 Type I Diabetes
5.1.3 Type II Diabetes
5.2 By Application - Global Biosimilars Insulin Revenue & Forecasts
5.2.1 By Application - Global Biosimilars Insulin Revenue, 2018-2023
5.2.2 By Application - Global Biosimilars Insulin Revenue, 2024-2029
5.2.3 By Application - Global Biosimilars Insulin Revenue Market Share, 2018-2029
5.3 By Application - Global Biosimilars Insulin Sales & Forecasts
5.3.1 By Application - Global Biosimilars Insulin Sales, 2018-2023
5.3.2 By Application - Global Biosimilars Insulin Sales, 2024-2029
5.3.3 By Application - Global Biosimilars Insulin Sales Market Share, 2018-2029
5.4 By Application - Global Biosimilars Insulin Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Biosimilars Insulin Market Size, 2022 & 2029
6.2 By Region - Global Biosimilars Insulin Revenue & Forecasts
6.2.1 By Region - Global Biosimilars Insulin Revenue, 2018-2023
6.2.2 By Region - Global Biosimilars Insulin Revenue, 2024-2029
6.2.3 By Region - Global Biosimilars Insulin Revenue Market Share, 2018-2029
6.3 By Region - Global Biosimilars Insulin Sales & Forecasts
6.3.1 By Region - Global Biosimilars Insulin Sales, 2018-2023
6.3.2 By Region - Global Biosimilars Insulin Sales, 2024-2029
6.3.3 By Region - Global Biosimilars Insulin Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Biosimilars Insulin Revenue, 2018-2029
6.4.2 By Country - North America Biosimilars Insulin Sales, 2018-2029
6.4.3 US Biosimilars Insulin Market Size, 2018-2029
6.4.4 Canada Biosimilars Insulin Market Size, 2018-2029
6.4.5 Mexico Biosimilars Insulin Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Biosimilars Insulin Revenue, 2018-2029
6.5.2 By Country - Europe Biosimilars Insulin Sales, 2018-2029
6.5.3 Germany Biosimilars Insulin Market Size, 2018-2029
6.5.4 France Biosimilars Insulin Market Size, 2018-2029
6.5.5 U.K. Biosimilars Insulin Market Size, 2018-2029
6.5.6 Italy Biosimilars Insulin Market Size, 2018-2029
6.5.7 Russia Biosimilars Insulin Market Size, 2018-2029
6.5.8 Nordic Countries Biosimilars Insulin Market Size, 2018-2029
6.5.9 Benelux Biosimilars Insulin Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Biosimilars Insulin Revenue, 2018-2029
6.6.2 By Region - Asia Biosimilars Insulin Sales, 2018-2029
6.6.3 China Biosimilars Insulin Market Size, 2018-2029
6.6.4 Japan Biosimilars Insulin Market Size, 2018-2029
6.6.5 South Korea Biosimilars Insulin Market Size, 2018-2029
6.6.6 Southeast Asia Biosimilars Insulin Market Size, 2018-2029
6.6.7 India Biosimilars Insulin Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Biosimilars Insulin Revenue, 2018-2029
6.7.2 By Country - South America Biosimilars Insulin Sales, 2018-2029
6.7.3 Brazil Biosimilars Insulin Market Size, 2018-2029
6.7.4 Argentina Biosimilars Insulin Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Biosimilars Insulin Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Biosimilars Insulin Sales, 2018-2029
6.8.3 Turkey Biosimilars Insulin Market Size, 2018-2029
6.8.4 Israel Biosimilars Insulin Market Size, 2018-2029
6.8.5 Saudi Arabia Biosimilars Insulin Market Size, 2018-2029
6.8.6 UAE Biosimilars Insulin Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Company Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Biosimilars Insulin Major Product Offerings
7.1.4 Eli Lilly Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly Key News & Latest Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Summary
7.2.2 Boehringer Ingelheim Business Overview
7.2.3 Boehringer Ingelheim Biosimilars Insulin Major Product Offerings
7.2.4 Boehringer Ingelheim Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.2.5 Boehringer Ingelheim Key News & Latest Developments
7.3 Biocon/Mylan
7.3.1 Biocon/Mylan Company Summary
7.3.2 Biocon/Mylan Business Overview
7.3.3 Biocon/Mylan Biosimilars Insulin Major Product Offerings
7.3.4 Biocon/Mylan Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.3.5 Biocon/Mylan Key News & Latest Developments
7.4 Gan & Lee Pharmaceuticals
7.4.1 Gan & Lee Pharmaceuticals Company Summary
7.4.2 Gan & Lee Pharmaceuticals Business Overview
7.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Major Product Offerings
7.4.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.4.5 Gan & Lee Pharmaceuticals Key News & Latest Developments
7.5 Tonghua Dongbao
7.5.1 Tonghua Dongbao Company Summary
7.5.2 Tonghua Dongbao Business Overview
7.5.3 Tonghua Dongbao Biosimilars Insulin Major Product Offerings
7.5.4 Tonghua Dongbao Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.5.5 Tonghua Dongbao Key News & Latest Developments
7.6 United Laboratories
7.6.1 United Laboratories Company Summary
7.6.2 United Laboratories Business Overview
7.6.3 United Laboratories Biosimilars Insulin Major Product Offerings
7.6.4 United Laboratories Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.6.5 United Laboratories Key News & Latest Developments
7.7 Sanofi
7.7.1 Sanofi Company Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Biosimilars Insulin Major Product Offerings
7.7.4 Sanofi Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.7.5 Sanofi Key News & Latest Developments
8 Global Biosimilars Insulin Production Capacity, Analysis
8.1 Global Biosimilars Insulin Production Capacity, 2018-2029
8.2 Biosimilars Insulin Production Capacity of Key Manufacturers in Global Market
8.3 Global Biosimilars Insulin Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Biosimilars Insulin Supply Chain Analysis
10.1 Biosimilars Insulin Industry Value Chain
10.2 Biosimilars Insulin Upstream Market
10.3 Biosimilars Insulin Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Biosimilars Insulin Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Biosimilars Insulin in Global Market
Table 2. Top Biosimilars Insulin Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Biosimilars Insulin Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Biosimilars Insulin Revenue Share by Companies, 2018-2023
Table 5. Global Biosimilars Insulin Sales by Companies, (K Units), 2018-2023
Table 6. Global Biosimilars Insulin Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Biosimilars Insulin Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Biosimilars Insulin Product Type
Table 9. List of Global Tier 1 Biosimilars Insulin Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Biosimilars Insulin Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Biosimilars Insulin Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Biosimilars Insulin Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Biosimilars Insulin Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Biosimilars Insulin Sales (K Units), 2018-2023
Table 15. By Type - Global Biosimilars Insulin Sales (K Units), 2024-2029
Table 16. By Application ? Global Biosimilars Insulin Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Biosimilars Insulin Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Biosimilars Insulin Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Biosimilars Insulin Sales (K Units), 2018-2023
Table 20. By Application - Global Biosimilars Insulin Sales (K Units), 2024-2029
Table 21. By Region ? Global Biosimilars Insulin Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Biosimilars Insulin Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Biosimilars Insulin Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Biosimilars Insulin Sales (K Units), 2018-2023
Table 25. By Region - Global Biosimilars Insulin Sales (K Units), 2024-2029
Table 26. By Country - North America Biosimilars Insulin Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Biosimilars Insulin Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Biosimilars Insulin Sales, (K Units), 2018-2023
Table 29. By Country - North America Biosimilars Insulin Sales, (K Units), 2024-2029
Table 30. By Country - Europe Biosimilars Insulin Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Biosimilars Insulin Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Biosimilars Insulin Sales, (K Units), 2018-2023
Table 33. By Country - Europe Biosimilars Insulin Sales, (K Units), 2024-2029
Table 34. By Region - Asia Biosimilars Insulin Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Biosimilars Insulin Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Biosimilars Insulin Sales, (K Units), 2018-2023
Table 37. By Region - Asia Biosimilars Insulin Sales, (K Units), 2024-2029
Table 38. By Country - South America Biosimilars Insulin Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Biosimilars Insulin Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Biosimilars Insulin Sales, (K Units), 2018-2023
Table 41. By Country - South America Biosimilars Insulin Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Biosimilars Insulin Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Biosimilars Insulin Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Biosimilars Insulin Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Biosimilars Insulin Sales, (K Units), 2024-2029
Table 46. Eli Lilly Company Summary
Table 47. Eli Lilly Biosimilars Insulin Product Offerings
Table 48. Eli Lilly Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Eli Lilly Key News & Latest Developments
Table 50. Boehringer Ingelheim Company Summary
Table 51. Boehringer Ingelheim Biosimilars Insulin Product Offerings
Table 52. Boehringer Ingelheim Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Boehringer Ingelheim Key News & Latest Developments
Table 54. Biocon/Mylan Company Summary
Table 55. Biocon/Mylan Biosimilars Insulin Product Offerings
Table 56. Biocon/Mylan Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Biocon/Mylan Key News & Latest Developments
Table 58. Gan & Lee Pharmaceuticals Company Summary
Table 59. Gan & Lee Pharmaceuticals Biosimilars Insulin Product Offerings
Table 60. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Gan & Lee Pharmaceuticals Key News & Latest Developments
Table 62. Tonghua Dongbao Company Summary
Table 63. Tonghua Dongbao Biosimilars Insulin Product Offerings
Table 64. Tonghua Dongbao Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Tonghua Dongbao Key News & Latest Developments
Table 66. United Laboratories Company Summary
Table 67. United Laboratories Biosimilars Insulin Product Offerings
Table 68. United Laboratories Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. United Laboratories Key News & Latest Developments
Table 70. Sanofi Company Summary
Table 71. Sanofi Biosimilars Insulin Product Offerings
Table 72. Sanofi Biosimilars Insulin Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Sanofi Key News & Latest Developments
Table 74. Biosimilars Insulin Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 75. Global Biosimilars Insulin Capacity Market Share of Key Manufacturers, 2021-2023
Table 76. Global Biosimilars Insulin Production by Region, 2018-2023 (K Units)
Table 77. Global Biosimilars Insulin Production by Region, 2024-2029 (K Units)
Table 78. Biosimilars Insulin Market Opportunities & Trends in Global Market
Table 79. Biosimilars Insulin Market Drivers in Global Market
Table 80. Biosimilars Insulin Market Restraints in Global Market
Table 81. Biosimilars Insulin Raw Materials
Table 82. Biosimilars Insulin Raw Materials Suppliers in Global Market
Table 83. Typical Biosimilars Insulin Downstream
Table 84. Biosimilars Insulin Downstream Clients in Global Market
Table 85. Biosimilars Insulin Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Biosimilars Insulin Segment by Type in 2022
Figure 2. Biosimilars Insulin Segment by Application in 2022
Figure 3. Global Biosimilars Insulin Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Biosimilars Insulin Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Biosimilars Insulin Revenue, 2018-2029 (US$, Mn)
Figure 7. Biosimilars Insulin Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Biosimilars Insulin Revenue in 2022
Figure 9. By Type - Global Biosimilars Insulin Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 11. By Type - Global Biosimilars Insulin Sales Market Share, 2018-2029
Figure 12. By Type - Global Biosimilars Insulin Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Biosimilars Insulin Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 15. By Application - Global Biosimilars Insulin Sales Market Share, 2018-2029
Figure 16. By Application - Global Biosimilars Insulin Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Biosimilars Insulin Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Biosimilars Insulin Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 20. By Region - Global Biosimilars Insulin Sales Market Share, 2018-2029
Figure 21. By Country - North America Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 22. By Country - North America Biosimilars Insulin Sales Market Share, 2018-2029
Figure 23. US Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Biosimilars Insulin Sales Market Share, 2018-2029
Figure 28. Germany Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 29. France Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Biosimilars Insulin Sales Market Share, 2018-2029
Figure 37. China Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 41. India Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 43. By Country - South America Biosimilars Insulin Sales Market Share, 2018-2029
Figure 44. Brazil Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Biosimilars Insulin Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Biosimilars Insulin Sales Market Share, 2018-2029
Figure 48. Turkey Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Biosimilars Insulin Revenue, (US$, Mn), 2018-2029
Figure 52. Global Biosimilars Insulin Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Biosimilars Insulin by Region, 2022 VS 2029
Figure 54. Biosimilars Insulin Industry Value Chain
Figure 55. Marketing Channels
